Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir
Emily S. Ford, William Simmons, Ellora Karmarkar, Leah H Yoke, Ayodale B Braimah, Johnnie J. Orozco, Cristina Maria Ghiuzeli, Serena Barnhill, Coralynn L Sack, Joshua O. Benditt, Pavitra Roychoudhury, Alexander L. Greninger, Adrienne E. Shapiro, Jennifer Hammond, James M. Rusnak, Mikael Dolsten, Michael Boeckh, Catherine Liu, Guang‐Shing Cheng, Lawrence Corey
Abstract
A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, intravenous (IV) remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.
Topics & Concepts
MedicineRitonavirDiseaseLymphoblastic LeukemiaCoronavirusLeukemiaCoronavirus disease 2019 (COVID-19)VirologyImmunologyInternal medicineInfectious disease (medical specialty)VirusViral loadAntiretroviral therapyRespiratory viral infections researchCOVID-19 Clinical Research StudiesNeutropenia and Cancer Infections